Utah-based molecular diagnostics firm Co-Diagnostics has confirmed that its existing line of COVID-19 polymerase chain reaction diagnostics remain effective in detecting the omicron coronavirus variant.
In a statement released by Co-Diagnostics, CEO Dwight Egan stated that the omicron variant, which has more than 50 mutations, does not interfere with the company's COVID-19 tests, including the following:
- The Original Logix Smart COVID-19 assay
- The SARS-CoV-2 2-gene test, the ABC (flu A/flu B/COVID-19) multiplex assay
- The COVID-19 extraction-free direct saliva test
- An in-development test to be used with an upcoming at-home/point-of-care device
The company also reported that it assessed the effectiveness of its products using publicly available sequencing data from the Global Initiative on Sharing All Influenza Data database.